Literature DB >> 1733610

Development of time-resolved immunofluorometric assay of vascular permeability factor.

K T Yeo1, T M Sioussat, J D Faix, D R Senger, T K Yeo.   

Abstract

We describe a two-site time-resolved immunofluorometric assay for guinea pig vascular permeability factor (VPF) for quantifying VPF in different biological fluids. Antibody against the carboxy terminus (C-IgG) is immobilized on microtiter wells, and antibody against the amino terminus (N-IgG) is labeled with Eu(3+)-chelate. Line 10 tumor culture medium, known to be rich in VPF, is assayed in a two-step incubation. Bound Eu3+ is then quantified by dissociation into a fluorescent enhancement solution, with measurement of the time-resolved fluorescence. The analytical sensitivity is 0.35 VPF unit, and the intra-assay CV is about 20%. The assay is specific for VPF, because pre-treatment with the appropriate C- or N-peptide, or pre-extraction of VPF, greatly decreases fluorescence. The VPF immunoassay is highly correlated (r2 = 0.94) with the Miles permeability assay, the classical bioassay of VPF. In addition, the immunofluorometric assay is about 30-fold more sensitive than the Miles assay.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733610

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  8 in total

1.  Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts.

Authors:  B Berse; J A Hunt; R J Diegel; P Morganelli; K Yeo; F Brown; R A Fava
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 2.  Tumor angiogenesis: the pivotal role of vascular endothelial growth factor.

Authors:  D Marmé
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

3.  Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo.

Authors:  M Kuroki; E E Voest; S Amano; L V Beerepoot; S Takashima; M Tolentino; R Y Kim; R M Rohan; K A Colby; K T Yeo; A P Adamis
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

4.  Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen.

Authors:  D T Shima; A P Adamis; N Ferrara; K T Yeo; T K Yeo; R Allende; J Folkman; P A D'Amore
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.354

Review 5.  Vascular permeability factor (VPF, VEGF) in tumor biology.

Authors:  D R Senger; L Van de Water; L F Brown; J A Nagy; K T Yeo; T K Yeo; B Berse; R W Jackman; A M Dvorak; H F Dvorak
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

6.  Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.

Authors:  J W Miller; A P Adamis; D T Shima; P A D'Amore; R S Moulton; M S O'Reilly; J Folkman; H F Dvorak; L F Brown; B Berse
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

7.  Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer.

Authors:  A Obermair; C Tempfer; L Hefler; O Preyer; A Kaider; R Zeillinger; S Leodolter; C Kainz
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

8.  Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.

Authors:  R A Fava; N J Olsen; G Spencer-Green; K T Yeo; T K Yeo; B Berse; R W Jackman; D R Senger; H F Dvorak; L F Brown
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.